Elicio Therapeutics
ELTX
53 hedge funds and large institutions have $20.3M invested in Elicio Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
13% more funds holding
Funds holding: 47 → 53 (+6)
0.04% less ownership
Funds ownership: 2.38% → 2.34% (-0.04%)
71% less capital invested
Capital invested by funds: $69.3M → $20.3M (-$49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.81M |
| 2 |
LSAG
Lake Street Advisors Group
Portsmouth,
New Hampshire
|
+$1.25M |
| 3 |
Renaissance Technologies
New York
|
+$966K |
| 4 |
Morgan Stanley
New York
|
+$616K |
| 5 |
Two Sigma Investments
New York
|
+$475K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$10.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$6.01M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.74M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.58M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$751K |
ELTX Hedge Fund Activity: Q4 2021 in Review
53 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q4 2021, worth a combined $20.3M — down 71% from $69.3M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ELTX positions and 12 closed out — a net gain of 6 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $5.81M. The largest seller was Park West Asset Management, exiting entirely with an estimated $10.2M sold.
- 53 institutional investors held Elicio Therapeutics (ELTX) as of Q4 2021, up from 47 in Q3 2021.
- Funds reported $20.3M of Elicio Therapeutics stock for Q4 2021, down 71% quarter-over-quarter.
- 18 funds opened new Elicio Therapeutics positions in Q4 2021 and 12 closed out, a net change of +6 holders.
- The largest Elicio Therapeutics buyer in Q4 2021 was Nantahala Capital Management, an estimated $5.81M added.
- The largest Elicio Therapeutics seller in Q4 2021 was Park West Asset Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2021.